MANNKIND CORP (MNKD)
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
MannKind Corporation
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 321.54M shares outstanding
USMannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments.
Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market.
The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Leadership
ANTHONY HOOPER
Director
Ajay Ahuja, M.D., MBA
Executive Vice President, Chief Medical Officer
Christine Mundkur
Director
Christopher B. Prentiss
Chief Financial Officer
Employees
403
Country
US
Sector
Healthcare
Website
mannkindcorp.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Binder Steven B. | Director | Sale | 39.1K | $128.5K | Sep 25, 2026 |
| Binder Steven B. | Director | Sale | 33.6K | $127.9K | Sep 10, 2026 |
| Binder Steven B. | Director | Sale | 39.1K | $158.5K | Aug 7, 2026 |
| Binder Steven B. | Director | Sale | 52.5K | $213.1K | Jul 17, 2026 |
 Thomson David | EVP Genl Counsel & Secretary | Sale | 24.1K | $97.6K | Jul 17, 2026 |
| Thomson David | EVP Genl Counsel & Secretary | Automatic Sell | 16.4K | $67.0K | Jul 15, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
BlackRock, Inc. | 32.1M | 10.0% | 13F |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Jan 2024 | 22.3M | 6.9% | 13G |
Rubric Capital Management LP | 18.0M | 5.6% | 13F |
Rubric Capital Management LP · also on 13F· joint filing· may incl. warrants· filed Sep 2026 | 18.0M | 5.6% | 13G |
STATE STREET CORP | 16.2M | 5.0% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 13.2M | 4.1% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 7.9M | 2.5% | 13F |
WELLINGTON MANAGEMENT GROUP LLP | 7.8M | 2.4% | 13F |
Frazier Life Sciences Management, L.P. | 6.6M | 2.1% | 13F |
Deep Track Capital, LP | 6.0M | 1.9% | 13F |
Insiders
- Binder Steven B.Director
- Thomson DavidEVP Genl Counsel & Secretary
- Castagna MichaelChief Executive Officer
- Tross Stuart AChief People & Workpl Officer
- Singh Sanjay REVP Technical Operations
- Marasco DominicPres, Endocrine Business Unit
- Prentiss Christopher BChief Financial Officer
- Consiglio Ronald JDirector
- Grancio JenniferDirector
- Friedman Michael ADirector
based on 321.54M shares outstanding
US30d Avg
4.59M
60d Avg
4.32M
90d Avg
4.34M